EB 101 - Abeona Therapeutics

Drug Profile

EB 101 - Abeona Therapeutics

Alternative Names: LZRSE COL7A1

Latest Information Update: 18 Apr 2017

Price : $50

At a glance

  • Originator Stanford University
  • Developer Abeona Therapeutics; Epidermolysis Bullosa Research Partnership; Stanford University
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epidermolysis bullosa
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Epidermolysis bullosa

Most Recent Events

  • 08 Mar 2017 EB 101 - Abeona Therapeutics receives Orphan Drug status for Epidermolysis bullosa in European Union
  • 08 Mar 2017 EB 101 receives Orphan Drug status for Epidermolysis bullosa (In adolescents, In adults) in USA
  • 02 Nov 2016 Pharmacodynamics data from part 1 of a phase II trial in Epidermolysis bullosa released by Abeona therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top